Emergent BioSolutions (LTS:0IGA) EPS (Basic): $-0.17 (TTM As of Mar. 2026)

What is Emergent BioSolutions EPS (Basic)?

Emergent BioSolutions LTS:0IGA +2.79% 54 EPS (Basic) is $-0.17 as of Mar. 2026. GuruFocus rates LTS:0IGA with a GF Score™ of 54/100 and a GF Value™ of $4.61 (Significantly Overvalued). The stock has 5 warning signs investors should review.

Emergent BioSolutions's basic earnings per share (Basic EPS) for the three months ended in Mar. 2026 was $0.13. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Mar. 2026 was $-0.17.

Emergent BioSolutions's EPS (Diluted) for the three months ended in Mar. 2026 was $0.07. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was $-0.28.

Emergent BioSolutions's EPS without NRI for the three months ended in Mar. 2026 was $0.21. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Mar. 2026 was 1.00.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 13 years, Emergent BioSolutions's highest 3-Year average EPS without NRI Growth Rate was 61.90% per year. The lowest was -18.80% per year. And the median was 21.20% per year.

Emergent BioSolutions (LTS:0IGA) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Emergent BioSolutions EPS (Basic) Related Terms

Emergent BioSolutions EPS (Basic) Historical Data

* Premium members only.

The historical data trend for Emergent BioSolutions's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Emergent BioSolutions EPS (Basic) Chart

Emergent BioSolutions Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

EPS (Basic)

Get a 7-Day Free Trial

4.10

-4.22

-14.85

-3.60

0.98

Emergent BioSolutions Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
EPS (Basic)	Get a 7-Day Free Trial															1.25	-0.22	0.96	-1.04	0.13

54GF Score

Emergent BioSolutions Inc LTS:0IGA

EPS (Basic) is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Emergent BioSolutions EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

Emergent BioSolutions's Basic EPS for the fiscal year that ended in Dec. 2025 is calculated as

Basic EPS (A: Dec. 2025 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(52.6	-	0)	/	53.500
	=	0.98

Emergent BioSolutions's Basic EPS for the quarter that ended in Mar. 2026 is calculated as

Basic EPS (Q: Mar. 2026 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(6.8	-	0)	/	51.900
	=	0.13

EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.17

Frequently Asked Questions Learn more about EPS (Basic) →

What does a EPS (Basic) of $-0.17 mean?

Emergent BioSolutions (LTS:0IGA) has a EPS (Basic) of $-0.17 as of Mar. 2026. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Emergent BioSolutions and its competitors.

Is Emergent BioSolutions' EPS (Basic) too high?

Emergent BioSolutions' current EPS (Basic) is $-0.17. Overall, Emergent BioSolutions has a GF Score™ of 54/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.

How does Emergent BioSolutions' EPS (Basic) compare to AQST and EOLS?

Emergent BioSolutions' EPS (Basic) of $-0.17 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good EPS (Basic) for a Drug Manufacturers company?

A good EPS (Basic) depends on the Drug Manufacturers industry context. However, EPS (Basic) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high EPS (Basic) mean?

A high EPS (Basic) can signal that a stock is expensive relative to its fundamentals. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Emergent BioSolutions and its competitors. Emergent BioSolutions's current EPS (Basic) is $-0.17. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Emergent BioSolutions stock overvalued right now?

Based on GuruFocus' analysis, Emergent BioSolutions (LTS:0IGA) is currently considered Significantly Overvalued. The stock's GF Value™ is $4.61, compared to a current price of $8.24 — trading 78.8% above its estimated fair value. The current EPS (Basic) is $-0.17. Emergent BioSolutions' overall GF Score™ is 54/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is EPS (Basic) calculated?

EPS (Basic) is calculated from a company's financial statements. For Emergent BioSolutions (LTS:0IGA), the current EPS (Basic) is $-0.17 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Emergent BioSolutions (LTS:0IGA) Overvalued in 2026?

Based on GuruFocus' analysis, Emergent BioSolutions stock appears to be overvalued. The current stock price of $8.24 is trading 78.8% above its estimated GF Value™ of $4.61. GuruFocus considers Emergent BioSolutions to be Significantly Overvalued.

Key valuation signals for LTS:0IGA:

EPS (Basic): $-0.17
GF Value™: $4.61 vs. price of $8.24 (78.8% above fair value)
GF Score™: 54/100 with 5 warning signs

No single metric tells the full story. See the LTS:0IGA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Emergent BioSolutions Business Description

Industry Healthcare Drug Manufacturers

Comparable Companies AQST EOLS ELTP IRWD SIGA ORGO TKNO TLRY AKBA NIKA XTER:MRK TSE:4502 XSWX:GALD SHSE:600276 NSE:SUNPHARMA XTAE:TEVA LSE:HLN XSWX:SDZ ZTS HKSE:03692

Other Exchanges EBS:USA ER4:Germany

Address 300 Professional Drive, Gaithersburg, MD, USA, 20879

Website https://www.emergentbiosolutions.com

Emergent BioSolutions Inc offers public health products to the government and healthcare providers. Company operates in three segments namely Commercial Product, MCM Products, and Services segment. The Commercial Product Segment consisting of Nasal Spray; the MCM Products Segment consisting of Anthrax-MCM products, Smallpox-MCM products and Other Products and the Services Segment consisting of Bioservices portfolio. Geographically, the company operates in United States, Canada, and Others. It derives maximum revenue from United states. The company's products include: NARCAN Nasal Spray, KLOXXADO Nasal Spray, ACAM2000, ANTHRASIL, BAT, BioThrax, CNJ-016, raxibacumab injection, Ebanga, and others.

54GF Score

Get the complete analysis for LTS:0IGA

EPS (Basic) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$8.24

Price

$4.61

GF Value

View LTS:0IGA Analysis

See EPS (Basic) data for all stocks →